Fig. 2From: Adjuvant therapy with gemcitabine and stereotactic body radiation therapy versus gemcitabine alone for resected stage II pancreatic cancer: a prospective, randomized, open-label, single center trialRecurrence-free survival (RFS) (a), locoregional recurrence-free survival (LRFS) (c), and overall survival (OS) (e) of the whole cohort; and RFS (b), LRFS (d), and OS (f) of node-positive patientsBack to article page